Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials

Venkatraman N., Tiono AB., Bowyer G., Bellamy DG., Stockdale LK., Powlson J., Collins KA., Coulibaly S., Datoo MS., Silman D., Ouedraogo A., Nébié I., Imoukhuede EB., Brod F., Folegatti P., Dickinson-Craig E., Jamieson S., Bougouma EC., Wright D., Diarra A., Bliss CM., Morter R., Glenn G., Fries LF., Reimer JM., Lövgren-Bengtsson K., Baker M., Poulton I., Moyle S., Berrie E., Green N., Mukhopadhyay E., Viebig NK., Angus B., Lawrie A., Roberts R., Gilbert SC., Lewis DJM., Sirima SB., Ewer KJ., Hill AVS.

DOI

10.1016/s2666-5247(24)00084-3

Type

Journal article

Journal

The Lancet Microbe

Publisher

Elsevier BV

Publication Date

01/2025

Pages

100868 - 100868

Permalink Original publication